Aktienanalyse zu OKYO Pharma Ltd (OKYO)OKYOOKYO Pharma Ltd

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

OKYO Pharma Ltd is a good buy right now, as it is currently priced at $1.46, which is well below its 52-week high of $3.20. The RSI is at 50.066, suggesting the stock is neither overbought nor oversold, which is favorable for potential upside. Additionally, the chairman's recent purchase of 25,000 shares at $1.40 indicates strong insider confidence, which could positively influence the stock's performance.